A Barcelona team at the Vall d'Hebron Institute of Research and a VHIR spinout called Endolipid Therapeutics published a short peptide called EDL6D ↗ in the Journal of Translational Medicine on Saturday that did two things in mice with established fatty liver disease. It reversed the fat. It blocked the early fibrosis markers. The peptide was designed to phenocopy a protein, sex hormone-binding globulin (SHBG), that circulates in human blood and is consistently low in patients with metabolic dysfunction-associated fatty liver disease, the condition formerly called NAFLD. Restoring SHBG itself is hard. It is a 90-kilodalton protein with a complex glycosylation pattern, and you cannot dose it like a small molecule. The team's bet was that a short peptide could carry the lipogenic-suppression part of SHBG's action without the steroid-binding part. The mouse data says it can.
The premise rests on a piece of older clinical observation. People with fatty liver disease have lower plasma SHBG. The correlation is well-established; whether SHBG actively suppresses hepatic fat synthesis or merely reflects insulin resistance has been the open question. The Selva group at VHIR has shown in earlier work that overexpressing human SHBG in mice does reduce hepatic lipid accumulation, which moves the answer toward causation. The translational problem was always the molecule itself. SHBG circulates as a glycosylated dimer with intricate post-translational chemistry, which is what makes it a useful steroid carrier but a non-starter as a therapeutic. Hence the peptide gambit.
What EDL6D does in cells
The team tested EDL6D on HepG2 cells, a human hepatoma line treated daily with 30 millimolar fructose, which forces the cells into a lipogenic mode that mimics MASLD physiology. EDL6D dropped four lipogenic markers at both mRNA and protein levels: ATP-citrate lyase (ACL), acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), and peroxisome proliferator-activated receptor gamma (PPARγ). In plain language, ACL, ACC, and FASN are three enzymes in a chain that turns dietary sugars into fatty acids in the liver, and PPARγ is the transcription factor that turns the whole program on. EDL6D turned all four off. Cells under heavy fructose load stopped accumulating triglycerides when exposed to the peptide. The hit pattern is consistent with the prior SHBG-overexpression results, which is what "phenocopying" was supposed to deliver.
In vivo, they ran the standard MASLD model: wild-type mice on a high-fat diet plus 30 percent fructose in drinking water, long enough to produce hepatic steatosis with early fibrosis. Two arms. The preventive arm gave EDL6D from the start of the diet; mice did not develop MASLD. The therapeutic arm let MASLD establish first and then started EDL6D; the existing liver fat regressed. The therapeutic arm is the harder result. Most candidates in this space prevent the lesion. Few actually reverse one that has already formed. The team also measured Col1a1 (collagen type I alpha 1) and TGF-β1 (transforming growth factor beta 1), the two markers most reliably elevated in the mild-fibrosis phase that precedes irreversible scarring. Both dropped in EDL6D-treated mice. That is the antifibrotic claim, early, in a mouse model, on a peptide the field is seeing for the first time.
Where this sits in the MASLD landscape
The fatty-liver field has organized in the past two years around two upstream interventions. Resmetirom, a thyroid hormone receptor beta agonist, became the first FDA-approved drug for the steatohepatitis form (MASH) in 2024. Semaglutide showed a fibrosis-improvement signal in MASH and was singled out by the European Association for the Study of Obesity in their May framework update ↗ for that specific indication. Tirzepatide cut liver fat in SYNERGY-NASH. All three sit upstream. GLP-1 agonism and TR-beta agonism move weight, insulin sensitivity, or thyroid-axis signaling, and the liver follows. EDL6D is a different bet. It targets the lipogenic transcriptional program directly, downstream of the metabolic upstream that GLP-1 drugs touch. If the result holds in larger animals, the implication is that MASLD has a second mechanistic class waiting under the lipogenesis ceiling, not just under the weight-loss ceiling.
Endolipid Therapeutics, the VHIR spinout that appears as a co-affiliation on every senior-author byline of the paper, is the commercial vehicle for this peptide. The paper identifies EDL6D as a preclinical lead compound, which is the language a spinout uses when it intends to take the molecule forward. The paper does not disclose the amino acid sequence, which is common when patent claims are pending. It also does not include pharmacokinetic data, no head-to-head against resmetirom, and no histological scoring against the NAS-CRN system that regulators expect in late-stage MASH trials. Each of those is what a follow-up paper or an IND-enabling package would need to deliver before this becomes a candidate rather than a lead. For now, the result is a preclinical peptide with the unusual property that it reverses the lesion rather than only preventing it.
What the paper does say, plainly: the low-SHBG observation in MASLD patients is now mechanistically operational, not just correlative. Someone built a peptide off the hypothesis and the mouse data did what the hypothesis predicted. Whether that translates is the next question, and the answer is years away.